Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + hydroxychloroquine
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC), and hydroxychloroquine, an autophagy inhibitor. Sacituzumab govitecan is composed of a humanized monoclonal antibody (sacituzumab) linked to the topoisomerase I inhibitor payload SN-38 (govitecan) via a pH-sensitive linker. It targets the Trophoblast cell-surface antigen 2 (Trop-2), which is frequently overexpressed in various solid tumors, including breast cancer. Hydroxychloroquine is an antimalarial agent that also acts as an autophagy inhibitor by preventing lysosomal acidification. In the context of advanced breast cancer, hydroxychloroquine is hypothesized to act synergistically with ADCs by inhibiting autophagy, a survival mechanism that cancer cells may employ to resist the cytotoxic effects of the ADC payload. This specific combination is being investigated in a Phase I/II clinical trial sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University for patients with advanced breast cancer who have progressed on prior therapies.
- Brand names
- Trodelvy + Plaquenil
- Other names
- SG + HCQ
02
Targets
NeuraminidaseTACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab govitecan + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + hydroxychloroquine.